

Antoinette MaassenVanDenBrink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1041422/publications.pdf>

Version: 2024-02-01

129
papers

5,265
citations

145106

33
h-index

124990

64
g-index

131
all docs

131
docs citations

131
times ranked

3761
citing authors

#	ARTICLE	IF	CITATIONS
1	CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 911-912.	0.9	10
2	Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. <i>Lancet Neurology</i> , The, 2022, 21, 284-294.	4.9	59
3	Validation of diagnostic ICHD-3 criteria for menstrual migraine. <i>Cephalalgia</i> , 2022, 42, 1184-1193.	1.8	17
4	European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. <i>Journal of Headache and Pain</i> , 2022, 23, .	2.5	143
5	Pain perception in women with menstrually-related migraine. <i>Cephalalgia</i> , 2021, 41, 417-421.	1.8	3
6	Position Paper on Post-Traumatic Headache: The Relationship Between Head Trauma, Stress Disorder, and Migraine. <i>Pain and Therapy</i> , 2021, 10, 1-13.	1.5	19
7	Sex differences in prevalence of migraine trigger factors: A cross-sectional study. <i>Cephalalgia</i> , 2021, 41, 643-648.	1.8	29
8	Evaluating rimegepant for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 973-979.	0.9	13
9	Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life: Implications for the efficacy and safety of novel antimigraine medications. <i>Maturitas</i> , 2021, 145, 73-77.	1.0	15
10	Dietary salt modifies the blood pressure response to renin-angiotensin inhibition in experimental chronic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, F654-F668.	1.3	8
11	Medication overuse and drug addiction: a narrative review from addiction perspective. <i>Journal of Headache and Pain</i> , 2021, 22, 32.	2.5	36
12	Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine. <i>Current Opinion in Neurology</i> , 2021, 34, 330-338.	1.8	7
13	E-diary use in clinical headache practice: A prospective observational study. <i>Cephalalgia</i> , 2021, 41, 1161-1171.	1.8	34
14	Selective Phosphodiesterase 1 Inhibition Ameliorates Vascular Function, Reduces Inflammatory Response, and Lowers Blood Pressure in Aging Animals. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2021, 378, 173-183.	1.3	9
15	Metabolic Aspects of Migraine: Association With Obesity and Diabetes Mellitus. <i>Frontiers in Neurology</i> , 2021, 12, 686398.	1.1	21
16	CGRP, adrenomedullin and adrenomedullin 2 display endogenous GPCR agonist bias in primary human cardiovascular cells. <i>Communications Biology</i> , 2021, 4, 776.	2.0	15
17	Comparing Perimenstrual and Nonperimenstrual Migraine Attacks Using an e-Diary. <i>Neurology</i> , 2021, 97, e1661-e1671.	1.5	26
18	Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study. <i>European Journal of Neurology</i> , 2021, 28, 4194-4203.	1.7	34

#	ARTICLE	IF	CITATIONS
19	Sex Differences in Response to Triptans. <i>Neurology</i> , 2021, 96, 162-170.	1.5	25
20	Clinical symptoms of androgen deficiency in men with migraine or cluster headache: a cross-sectional cohort study. <i>Journal of Headache and Pain</i> , 2021, 22, 125.	2.5	5
21	Sex Differences in Risk Profile, Stroke Cause and Outcome in Ischemic Stroke Patients With and Without Migraine. <i>Frontiers in Neuroscience</i> , 2021, 15, 740639.	1.4	4
22	Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study. <i>Journal of Headache and Pain</i> , 2021, 22, 152.	2.5	6
23	Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. <i>Cephalalgia</i> , 2020, 40, 357-366.	1.8	44
24	Increased Mortality and Vascular Phenotype in a Knock-In Mouse Model of Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations. <i>Stroke</i> , 2020, 51, 300-307.	1.0	5
25	European Headache Federation recommendations for placebo and nocebo terminology. <i>Journal of Headache and Pain</i> , 2020, 21, 117.	2.5	25
26	Persistent post-traumatic headache: a migrainous loop or not? The preclinical evidence. <i>Journal of Headache and Pain</i> , 2020, 21, 90.	2.5	24
27	The potential danger of blocking CGRP for treating migraine in CADASIL patients. <i>Cephalalgia</i> , 2020, 40, 1676-1678.	1.8	9
28	Migraine and other headache disorders in pregnancy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2020, 172, 187-199.	1.0	10
29	CGRP inhibitors for migraine prophylaxis: a safety review. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1237-1250.	1.0	30
30	Targeting CGRP in migraine: a matter of choice and dose. <i>Lancet Neurology</i> , The, 2020, 19, 712-713.	4.9	12
31	Giving Researchers a Headache – Sex and Gender Differences in Migraine. <i>Frontiers in Neurology</i> , 2020, 11, 549038.	1.1	59
32	Jealousy in women with migraine: a cross-sectional case-control study. <i>Journal of Headache and Pain</i> , 2020, 21, 51.	2.5	4
33	European headache federation consensus on the definition of resistant and refractory migraine. <i>Journal of Headache and Pain</i> , 2020, 21, 76.	2.5	126
34	Potential Mechanisms Involved in Palmitoylethanolamide-Induced Vasodepressor Effects in Rats. <i>Journal of Vascular Research</i> , 2020, 57, 152-163.	0.6	14
35	Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. , 2020, 211, 107528.		109
36	Anti-migraine Calcitonin Gene-Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice. <i>Annals of Neurology</i> , 2020, 88, 771-784.	2.8	64

#	ARTICLE	IF	CITATIONS
37	The role of purinergic P2Y ₁₂ and P2Y ₁₃ receptors in ADP ² S-induced inhibition of the cardioaccelerator sympathetic drive in pithed rats. <i>Purinergic Signalling</i> , 2020, 16, 73-84.	1.1	5
38	Headache medication and the COVID-19 pandemic. <i>Journal of Headache and Pain</i> , 2020, 21, 38.	2.5	54
39	Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. <i>Pain</i> , 2020, 161, 1092-1099.	2.0	61
40	Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence. <i>Journal of Headache and Pain</i> , 2020, 21, 55.	2.5	37
41	Headache and hormones, including pregnancy and breastfeeding. , 2020, , 484-493.		1
42	Current understanding of meningeal and cerebral vascular function underlying migraine headache. <i>Cephalalgia</i> , 2019, 39, 1606-1622.	1.8	76
43	Characterization of binding, functional activity, and contractile responses of the selective 5-HT _{1F} receptor agonist lasmiditan. <i>British Journal of Pharmacology</i> , 2019, 176, 4681-4695.	2.7	51
44	Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries. <i>Cephalalgia</i> , 2019, 39, 1735-1744.	1.8	29
45	CGRP-targeted antibodies in difficult-to-treat migraine. <i>Nature Reviews Neurology</i> , 2019, 15, 688-689.	4.9	13
46	Cardio- and cerebrovascular safety of erenumab, a monoclonal antibody targeting CGRP receptors – important studies on human isolated arteries. <i>Cephalalgia</i> , 2019, 39, 1731-1734.	1.8	8
47	Functional Characterization of the Prejunctional Receptors Mediating the Inhibition by Ergotamine of the Rat Perivascular Sensory Peptidergic Drive. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3173-3182.	1.7	6
48	The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse. <i>Journal of Headache and Pain</i> , 2019, 20, 54.	2.5	23
49	Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models. <i>Cephalalgia</i> , 2019, 39, 1421-1434.	1.8	25
50	Effects of two isometheptene enantiomers in isolated human blood vessels and rat middle meningeal artery – potential antimigraine efficacy. <i>Journal of Headache and Pain</i> , 2019, 20, 47.	2.5	0
51	Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. <i>Regulatory Toxicology and Pharmacology</i> , 2019, 106, 224-238.	1.3	33
52	Coronary artery calcification in middle-aged women with premature ovarian insufficiency. <i>Clinical Endocrinology</i> , 2019, 91, 314-322.	1.2	18
53	Extracranial Trigger Site Surgery for Migraine: A Systematic Review With Meta-Analysis on Elimination of Headache Symptoms. <i>Frontiers in Neurology</i> , 2019, 10, 89.	1.1	9
54	Understanding CGRP and Cardiovascular Risk. <i>Handbook of Experimental Pharmacology</i> , 2019, 255, 131-140.	0.9	13

#	ARTICLE	IF	CITATIONS
55	Cardiovascular Risk of Migraine in Men and Women. <i>Headache</i> , 2019, , 17-29.	0.2	1
56	Trigeminovascular calcitonin gene-related peptide function in <i>Cacna1a</i> R192Q-mutated knock-in mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 718-729.	2.4	12
57	Gender aspects of CGRP in migraine. <i>Cephalalgia</i> , 2019, 39, 435-444.	1.8	86
58	Protective effects of PACAP in ischemia. <i>Journal of Headache and Pain</i> , 2018, 19, 19.	2.5	40
59	Is selective 5-HT _{1F} receptor agonism an entity apart from that of the triptans in antimigraine therapy?. , 2018, 186, 88-97.		85
60	Calcitonin-gene-related peptide pathway mAbs and migraine prevention. <i>Current Opinion in Neurology</i> , 2018, 31, 274-280.	1.8	24
61	Side effects associated with current and prospective antimigraine pharmacotherapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 25-41.	1.5	74
62	Is CGRP Receptor Blockade Cardiovascularly Safe? Appropriate Studies Are Needed. <i>Headache</i> , 2018, 58, 1257-1258.	1.8	23
63	Characterization of the trigeminovascular actions of several adenosine A _{2A} receptor antagonists in an in vivo rat model of migraine. <i>Journal of Headache and Pain</i> , 2018, 19, 41.	2.5	20
64	Female sex hormones in men with migraine. <i>Neurology</i> , 2018, 91, e374-e381.	1.5	44
65	Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of α_2 -adrenoceptors and 5-HT ₁ receptors. <i>Journal of Headache and Pain</i> , 2018, 19, 40.	2.5	6
66	Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment. <i>Genome Medicine</i> , 2018, 10, 10.	3.6	8
67	PACAP38 and PAC1 receptor blockade: a new target for headache?. <i>Journal of Headache and Pain</i> , 2018, 19, 64.	2.5	59
68	Migraine and cardiovascular disease in women. <i>Maturitas</i> , 2017, 97, 28-31.	1.0	35
69	A Licence to Prescribe. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1860-1861.	1.1	21
70	Blocking CGRP in migraine patients – a review of pros and cons. <i>Journal of Headache and Pain</i> , 2017, 18, 96.	2.5	217
71	Calcitonin Gene-Related Peptide Receptor Agonism. <i>Circulation</i> , 2017, 136, 384-387.	1.6	2
72	Pharmacological analysis of the inhibition produced by moxonidine and agmatine on the vasodepressor sensory CGRPergic outflow in pithed rats. <i>European Journal of Pharmacology</i> , 2017, 812, 97-103.	1.7	1

#	ARTICLE	IF	CITATIONS
73	Pharmacological analysis of the increases in heart rate and diastolic blood pressure produced by (S)-isometheptene and (R)-isometheptene in pithed rats. <i>Journal of Headache and Pain</i> , 2017, 18, 52.	2.5	6
74	The influence of migraine and female hormones on capsaicin-induced dermal blood flow. <i>Cephalalgia</i> , 2017, 37, 1164-1172.	1.8	34
75	The role of $\hat{1}$ - and $\hat{2}$ -adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats. <i>Journal of Headache and Pain</i> , 2017, 18, 104.	2.5	6
76	Wiping Out CGRP: Potential Cardiovascular Risks. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 779-788.	4.0	179
77	Comment on "A second trigeminal CGRP receptor: function and expression of the AMY1 receptor". <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 307-308.	1.7	12
78	Dihydroergotamine and sumatriptan in isolated human coronary artery, middle meningeal artery and saphenous vein. <i>Cephalalgia</i> , 2015, 35, 182-189.	1.8	14
79	Reduced trigeminovascular cyclicity in patients with menstrually related migraine. <i>Neurology</i> , 2015, 84, 125-131.	1.5	39
80	Inhibitory effect of chronic oral treatment with fluoxetine on capsaicin-induced external carotid vasodilatation in anaesthetised dogs. <i>Cephalalgia</i> , 2015, 35, 1041-1053.	1.8	3
81	Methylation of Migraine-Related Genes in Different Tissues of the Rat. <i>PLoS ONE</i> , 2014, 9, e87616.	1.1	22
82	Role of Prejunctional CB ₁ , But not CB ₂ , TRPV1 or GPR55 Receptors in Anandamide-Induced Inhibition of the Vasodepressor Sensory CGRPergic Outflow in Pithed Rats. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 114, 240-247.	1.2	10
83	Cranioselectivity of Sumatriptan Revisited: Pronounced Contractions to Sumatriptan in Small Human Isolated Coronary Artery. <i>CNS Drugs</i> , 2014, 28, 273-278.	2.7	14
84	Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead. <i>Cephalalgia</i> , 2014, 34, 514-522.	1.8	17
85	Glutamate Receptor Antagonists in the Management of Migraine. <i>Drugs</i> , 2014, 74, 1165-1176.	4.9	40
86	Migraine and perimenopause. <i>Maturitas</i> , 2014, 78, 277-280.	1.0	23
87	Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats. <i>European Journal of Pharmacology</i> , 2013, 721, 168-177.	1.7	23
88	Long-lasting physiological antagonism of calcitonin gene-related peptide towards endothelin-1 in rat mesenteric arteries and human coronary arteries. <i>European Journal of Pharmacology</i> , 2013, 720, 303-309.	1.7	9
89	Intracranial and extracranial arteries in migraine. <i>Lancet Neurology</i> , The, 2013, 12, 847-848.	4.9	7
90	Analysis of the vascular responses in a murine model of polycystic ovary syndrome. <i>Journal of Endocrinology</i> , 2013, 218, 205-213.	1.2	16

#	ARTICLE	IF	CITATIONS
91	Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1309-1323.	2.5	3
92	Basic mechanisms of migraine and its acute treatment. , 2012, 136, 319-333.		119
93	Dihydroergotamine, Ergotamine, Methysergide and Sumatriptan " Basic Science in Relation to Migraine Treatment. <i>Headache</i> , 2012, 52, 707-714.	1.8	61
94	Serotonin, NO, and CGRP and Headache. <i>Headache</i> , 2011, 51, 1046-1048.	1.8	1
95	Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects. , 2011, 129, 332-351.		58
96	Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. <i>Cephalalgia</i> , 2011, 31, 181-189.	1.8	65
97	Mechanisms of Migraine and Its Treatment. , 2011, , 239-253.		0
98	Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. <i>Cephalalgia</i> , 2010, 30, 1233-1240.	1.8	72
99	Spinal sumatriptan inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors. <i>European Journal of Pharmacology</i> , 2009, 615, 133-138.	1.7	16
100	Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. <i>European Journal of Pharmacology</i> , 2009, 619, 61-67.	1.7	28
101	Current and prospective pharmacological targets in relation to antimigraine action. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 378, 371-394.	1.4	28
102	Neurovascular pharmacology of migraine. <i>European Journal of Pharmacology</i> , 2008, 585, 313-319.	1.7	11
103	Crosstalk of vascular 5-HT1 receptors with other receptors: Clinical implications. <i>Neuropharmacology</i> , 2008, 55, 986-993.	2.0	18
104	Female Sex Hormones and Rat Dural Vasodilatation to CGRP, Periarterial Electrical Stimulation and Capsaicin. <i>Headache</i> , 2007, 47, 225-235.	1.8	39
105	The Phe-124-Cys and A-161T Variants of the Human 5-HT1B Receptor Gene Are Not Major Determinants of the Clinical Response to Sumatriptan. <i>Headache</i> , 2007, 47, 711-716.	1.8	15
106	Potential role of female sex hormones in the pathophysiology of migraine. , 2007, 113, 321-340.		83
107	Pharmacological characterisation of capsaicin-induced relaxations in human and porcine isolated arteries. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2007, 375, 29-38.	1.4	34
108	Characterisation of CGRP receptors in the human isolated middle meningeal artery. <i>Life Sciences</i> , 2006, 79, 265-271.	2.0	47

#	ARTICLE	IF	CITATIONS
109	Functional reactivity of 5-HT receptors in human umbilical cord and maternal subcutaneous fat arteries after normotensive or pre-eclamptic pregnancy. <i>Journal of Hypertension</i> , 2006, 24, 1345-1353.	0.3	31
110	Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2006, 374, 163-175.	1.4	14
111	Characterisation of CGRP receptors in human and porcine isolated coronary arteries: Evidence for CGRP receptor heterogeneity. <i>European Journal of Pharmacology</i> , 2006, 530, 107-116.	1.7	55
112	Potential vascular $\hat{1}\pm 1$ -adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat. <i>European Journal of Pharmacology</i> , 2006, 535, 234-242.	1.7	27
113	Clonidine inhibits the canine external carotid vasodilatation to capsaicin by $\hat{1}\pm 2A/2C$ -adrenoceptors. <i>European Journal of Pharmacology</i> , 2006, 543, 68-76.	1.7	9
114	Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT _{1B/1D} Agonists) in the Acute Treatment of Migraine. <i>Headache</i> , 2004, 44, 414-425.	1.8	327
115	Coronary Vasoconstrictor Potential of Triptans: A Review of In Vitro Pharmacologic Data. <i>Headache</i> , 2004, 44, S13-S19.	1.8	40
116	Calcitonin gene-related peptide and its role in migraine pathophysiology. <i>European Journal of Pharmacology</i> , 2004, 500, 315-330.	1.7	150
117	Comparison of contractile responses to donitriptan and sumatriptan in the human middle meningeal and coronary arteries. <i>European Journal of Pharmacology</i> , 2002, 443, 125-132.	1.7	7
118	Human Isolated Coronary Artery Contraction to Sumatriptan Characterised by the Selective 5-HT _{1B/1D} Receptor Antagonist GR55562. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2000, 86, 287-290.	0.0	14
119	Pharmacological analysis of contractile effects of eletriptan and sumatriptan on human isolated blood vessels. <i>European Journal of Pharmacology</i> , 2000, 407, 165-173.	1.7	31
120	BMS-181885, a 5-HT _{1B/1D} receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential. <i>European Journal of Pharmacology</i> , 1998, 351, 329-339.	1.7	9
121	Influence of electrode site and size on variability of magnetic evoked potentials. , 1998, 21, 1779-1782.		13
122	5-HT _{1B} Receptor Polymorphism and Clinical Response to Sumatriptan. <i>Headache</i> , 1998, 38, 288-291.	1.8	60
123	Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs. <i>Circulation</i> , 1998, 98, 25-30.	1.6	314
124	70th Scientific Sessions of the American Heart Association. Expert Opinion on Investigational Drugs, 1998, 7, 117-120.	1.9	4
125	69th Scientific Sessions of the American Heart Association. Expert Opinion on Investigational Drugs, 1997, 6, 87-90.	1.9	0
126	Effects of avitriptan, a new 5-HT _{1B/1D} receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1997, 355, 295-302.	1.4	32

#	ARTICLE	IF	CITATIONS
127	Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. <i>British Journal of Pharmacology</i> , 1996, 119, 855-862.	2.7	41
128	Angiotensin-Converting Enzyme in the Human Heart. <i>Circulation</i> , 1995, 92, 1387-1388.	1.6	622
129	Emerging ipsilateral corticospinal pathways after stroke?. <i>Annals of Neurology</i> , 1994, 36, 448-448.	2.8	0